Combined PD-1 and CCR5 Inhibition for the Treatment of Refractory Microsatellite Stable mCRC

NCT03274804 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer
MSS

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Maraviroc

Sponsor

University Hospital Heidelberg

Collaborators

[object Object]